The use of venetoclax (ABT-199) in the treatment of CLL
Can we apply knowledge on CLL to other types of cancers?
Exploiting signalling pathways involved in CLL to develop novel therapies
Highlights from the International Workshop of the German CLL Study Group
Are complex karyotypes reliable prognostic markers for CLL?